RecruitingNCT06440148

Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Role of Sclerostin in Mastocytosis Bone Disease


Sponsor

Medical University of Lublin

Enrollment

50 participants

Start Date

Sep 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called SCLEROSTIN for people with bones and mastocytosis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSCLEROSTIN

Pathogenesis of mastocytosis bone disease


Locations(1)

Department of Hematooncology and Bone Marrow Transplantation

Lublin, Lublin Voivodeship, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06440148


Related Trials